Core Points - The company is set to lift the restrictions on 165,470,085 shares, which accounts for 22.31% of the total share capital [2][6] - The shares will be available for trading starting from September 5, 2025 [3][6] - The shares were issued at a price of 5.85 RMB per share during a private placement approved by the China Securities Regulatory Commission [4] Group 1: Basic Information on Restricted Shares - The restricted shares were issued to the controlling shareholder, Mr. Qin Benjun, as part of a private placement [4] - There have been no adjustments to the number of restricted shares due to events such as share buybacks or stock dividends since the issuance [4][5] Group 2: Compliance and Commitments - Mr. Qin Benjun has fulfilled all commitments related to the restricted shares, with no violations affecting the lifting of restrictions [5] - The sponsor institution has verified that the lifting of restrictions complies with relevant regulations and the commitments made during the private placement [7] Group 3: Future Implications - The lifting of restrictions will alter the company's share capital structure, with the final details to be confirmed by the Shenzhen branch of the China Securities Depository and Clearing Corporation [6][7]
桂林莱茵生物科技股份有限公司 关于非公开发行限售股份解除限售上市流通的提示性公告